The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

12 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.EBI
Laboratorios Dr. Esteve
5-(2'-Pyridyl)-2-aminothiazoles: alkyl amino sulfonamides and sulfamides as potent NPY(5) antagonists.EBI
Lundbeck Research Usa
Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.EBI
Lundbeck Research Usa
Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.EBI
Tsukuba Research Institute
Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.EBI
Tsukuba Research Institute
Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.EBI
Novartis Pharma
In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist.EBI
Pfizer
Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity.EBI
Astrazeneca
Discovery of potent and selective small molecule NPY Y5 receptor antagonists.EBI
Lundbeck Research Usa
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.EBI
Novartis Pharma
Pharmacological treatment of obesity: therapeutic strategies.EBI
The R. W. Johnson Pharmaceutical Research Institute